University of Southern California
USC Norris Comprehensive Cancer Center


Not logged in...


If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial CTSU-EA6174


Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Gino In, M.D.-Fellow
Other Trial Staff:  Charlean Ketchens, Coordinator, Raluca Agafitei, Coordinator, Marile Garcia, Coordinator, Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Diana Oganyesyan, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.